Close Menu

More articles about Business, Policy & Funding

The company said it will use the funding to continue development of its computational technologies, biomarkers, and diagnostics, as well as for new hires.

The funding will be used to validate the Simplexa COVID-19 Direct kit and Simplexa COVID-19 & Flu A/B Direct kit and to submit them to the FDA for 510(k) clearance.

ZeptoMetrix develops and manufactures quality control standards and verification panels used in infectious disease molecular diagnostic testing.

The company also projected full year 2020 revenue of between $84 million and 86 million and said that its instrument install base grew 34 percent over the year.

Despite the Q4 revenue increase, sales for FY2020 dropped 13 percent year over year to $5.2 million.

Qiagen discussed what's in store after a failed bid by Thermo Fisher Scientific, and COVID-19 remained a hot topic on the second day of the virtual conference.

The partners will use PacBio's HiFi sequencing to develop assays for carrier screening, evaluating immune system responses, and diagnosing heritable diseases.

The fluoro-enzyme immunoassay is designed for the qualitative and semi-quantitative detection of immunoglobulin G against SARS-CoV-2.

Hologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own.

Ortho said that it currently can deliver 5 million tests per month and will be able to increase that figure to 15 million tests per month in February.

Federal prosecutors alleged AutoGenomics paid nursing home patients to get tested in exchange for being referred for testing.

The kits are designed to run on Theradiag's i-Track 10 testing system and the IDS-iSYS automated analyzer from Immunodiagnostic Systems.

The lateral flow test can be used at the point of care and provides results within 15 minutes without the need for additional equipment, the company said.

HemoScreen is a portable, point-of-care complete blood count analyzer that uses disposable cartridges that include all necessary reagents.

The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.

The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.

During the quarter, the Tucson, Arizona-based company added 45 instruments for a total of 268 revenue-generating instruments installed in the US.

Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay. 

Separately, Siemens said that it has received CE marking for the use of its Clinitest Rapid COVID-19 Antigen Test with an additional specimen type.

For full-year 2020, the company expects revenues of approximately $417 million, which would be up 25 percent from a year ago.

Pages